AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Tensiomyography of Gastrocnemius in Lumbar Radiculopathy

Recruitingn/aAges 18 Years - 55 YearsAllCairo University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This cross-sectional study aims to evaluate the neuromuscular characteristics of the gastrocnemius muscles in individuals with chronic lumbar radiculopathy using tensiomyography (TMG). By analyzing parameters such as muscle contraction time, displacement, and relaxation time, the study seeks to understand potential alterations in muscle properties that may contribute to functional limitations in this patient population. Findings from this research may provide valuable insights into the role of gastrocnemius muscles in neuromuscular dysfunction and inform tailored rehabilitation strategies.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18-55 years. * Clinical diagnosis of chronic lumbar radiculopathy confirmed by MRI and clinical examination. * Presence of symptoms for more than 12 weeks. * One limb is affected by the condition, while the other limb is unaffected and will serve as the control. Exclusion Criteria: * โ— Acute lumbar radiculopathy (symptoms less than 12 weeks). * History of lower limb surgery or severe musculoskeletal disorders affecting the plantar flexor muscles. * Neurological disorders other than lumbar radiculopathy (e.g., peripheral neuropathy, multiple sclerosis). * Severe comorbid conditions that might interfere with the study (e.g., uncontrolled diabetes, severe cardiovascular disease). * Pregnant or breastfeeding women. * Participation in another clinical trial within the last 30 days. * Use of medications that could affect muscle function (e.g., corticosteroids, muscle relaxants).
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
Cleopatra October Hospital
Sixth of October, Egypt
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy